Management of hepatocellular carcinoma from diagnosis in routine clinical practice

Tasneem Lokhandwala; Abdalla Aly; Eileen Farrelly; Joanne P Willey; Lois E Lamerato; Marcus Healey; Anna D Coutinho; Brian S Seal

doi:10.2217/hep-2021-0011

Management of hepatocellular carcinoma from diagnosis in routine clinical practice

Hepat Oncol. 2023 Mar 27;9(4):HEP45. doi: 10.2217/hep-2021-0011. eCollection 2022 Dec.

Authors

Tasneem Lokhandwala¹, Abdalla Aly², Eileen Farrelly¹, Joanne P Willey¹, Lois E Lamerato³, Marcus Healey², Anna D Coutinho¹, Brian S Seal²

Affiliations

¹ Xcenda LLC, Carrollton, TX 75010, USA.
² AstraZeneca PLC, Gaithersburg, MD 20878, USA.
³ Henry Ford Health System, Detroit, MI 48202, USA.

Abstract

Aim: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.

Materials & methods: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.

Results: Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy.

Conclusion: This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.

Keywords: Child-Pugh class; hepatocellular carcinoma; liver resection/excision; liver transplantation; locoregional therapies; overall survival; radiofrequency ablation; transarterial chemoembolization; transarterial radioembolization; treatment journey.